BGI Genomics Co Ltd Asset Resilience Ratio
BGI Genomics Co Ltd asset resilience ratio. BGI Genomics Co Ltd (300676) has an Asset Resilience Ratio of 3.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BGI Genomics Co Ltd (300676) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BGI Genomics Co Ltd (2015–2025)
Asset resilience ratio of BGI Genomics Co Ltd from 2015 to 2025. This chart shows how BGI Genomics Co Ltd's Asset Resilience Ratio has changed over time. See 300676 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down BGI Genomics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300676 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥411.01 Million | 3.62% |
| Total Liquid Assets | CN¥411.01 Million | 3.62% |
Asset Resilience Insights
- Limited Liquidity: BGI Genomics Co Ltd maintains only 3.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BGI Genomics Co Ltd Industry Peers by Asset Resilience Ratio
Compare BGI Genomics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Microba Life Sciences Ltd
AU:MAP |
Diagnostics & Research | 11.53% |
BGI Genomics Co Ltd Asset Resilience Ratio by Year (2015–2025)
BGI Genomics Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for BGI Genomics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.19% | CN¥492.42 Million ≈ $72.06 Million |
CN¥11.75 Billion ≈ $1.72 Billion |
+1.20pp |
| 2024-12-31 | 2.99% | CN¥375.12 Million ≈ $54.89 Million |
CN¥12.54 Billion ≈ $1.84 Billion |
-2.54pp |
| 2023-12-31 | 5.54% | CN¥753.58 Million ≈ $110.27 Million |
CN¥13.61 Billion ≈ $1.99 Billion |
-3.03pp |
| 2022-12-31 | 8.56% | CN¥1.23 Billion ≈ $180.27 Million |
CN¥14.39 Billion ≈ $2.10 Billion |
-5.81pp |
| 2021-12-31 | 14.38% | CN¥2.05 Billion ≈ $299.84 Million |
CN¥14.25 Billion ≈ $2.09 Billion |
+6.30pp |
| 2019-12-31 | 8.07% | CN¥482.22 Million ≈ $70.56 Million |
CN¥5.97 Billion ≈ $874.29 Million |
-0.82pp |
| 2018-12-31 | 8.89% | CN¥456.23 Million ≈ $66.76 Million |
CN¥5.13 Billion ≈ $751.29 Million |
-25.46pp |
| 2017-12-31 | 34.34% | CN¥1.76 Billion ≈ $256.90 Million |
CN¥5.11 Billion ≈ $748.02 Million |
-3.69pp |
| 2016-12-31 | 38.03% | CN¥1.61 Billion ≈ $235.43 Million |
CN¥4.23 Billion ≈ $619.00 Million |
-9.52pp |
| 2015-12-31 | 47.56% | CN¥1.86 Billion ≈ $272.16 Million |
CN¥3.91 Billion ≈ $572.28 Million |
-- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more